National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Adverse Drug Events (ADE) (1)
- Adverse Events (1)
- (-) Arthritis (39)
- Cancer (1)
- Cancer: Cervical Cancer (1)
- Cardiovascular Conditions (1)
- Children/Adolescents (1)
- Chronic Conditions (3)
- Clinician-Patient Communication (2)
- Communication (2)
- Comparative Effectiveness (15)
- Decision Making (3)
- Diabetes (1)
- Elderly (1)
- Eye Disease and Health (1)
- Healthcare-Associated Infections (HAIs) (2)
- Healthcare Cost and Utilization Project (HCUP) (1)
- Healthcare Costs (1)
- Health Information Technology (HIT) (1)
- Health Literacy (2)
- Health Status (1)
- Heart Disease and Health (1)
- Hepatitis (1)
- Hospital Readmissions (1)
- Imaging (1)
- Medicare (2)
- Medication (12)
- Obesity (1)
- Outcomes (4)
- Pain (8)
- Patient-Centered Outcomes Research (14)
- Patient and Family Engagement (2)
- Patient Safety (5)
- Practice Patterns (1)
- Prevention (1)
- Quality of Care (1)
- Racial and Ethnic Minorities (1)
- Registries (5)
- Research Methodologies (2)
- Respiratory Conditions (1)
- Risk (7)
- Sex Factors (1)
- Sleep Problems (1)
- Stroke (1)
- Surgery (8)
- Treatments (1)
- Vaccination (1)
- Women (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 25 of 39 Research Studies DisplayedYun H, Xie F, Delzell E
The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population.
Older and disabled rheumatoid arthritis (RA) patients are often not present in large numbers in clinical trials or registries. Using a novel, claims-based clinical effectiveness algorithm with the potential to compare the effectiveness of different biologics among this population using large administrative databases, researchers found that abatacept, adalimumab and etanercept are more effective than infliximab among RA patients initiating biologics.
AHRQ-funded; HS021694; HS023009; HS018517.
Citation: Yun H, Xie F, Delzell E .
The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population.
Br J Clin Pharmacol 2015 Dec;80(6):1447-57. doi: 10.1111/bcp.12709.
.
.
Keywords: Comparative Effectiveness, Patient-Centered Outcomes Research, Elderly, Arthritis, Medicare
Curtis JR, Sarsour K, Napalkov P
Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study.
Interstitial lung disease (ILD) is a common extra-articular condition in rheumatoid arthritis (RA), but few studies have systematically investigated its incidence and risk factors in patients receiving anti-tumor necrosis factor-alpha (anti-TNFα) agents or alternate mechanisms of action (MOAs). After examining 13,795 episodes of biologic exposure in 11,219 patients, researchers found no significant differences in the risk of ILD and its related complications between RA patients receiving anti-TNFα agents and those receiving alternate MOA agents.
AHRQ-funded; HS018517.
Citation: Curtis JR, Sarsour K, Napalkov P .
Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study.
Arthritis Res Ther 2015 Nov 11;17:319. doi: 10.1186/s13075-015-0835-7..
Keywords: Arthritis, Comparative Effectiveness, Medication, Respiratory Conditions, Risk
Christensen R, Maxwell LJ, Juni P
Consensus on the need for a hierarchical list of patient-reported pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective.
A group of international experts convened to address issues regarding the need to develop hierarchical lists of outcome measurement instruments for a particular outcome for metaanalyses. After discussions, most participants agreed that there is a need to develop a methodology for generation of hierarchical lists of outcome measurement instruments to guide metaanalyses.
AHRQ-funded; HS021110.
Citation: Christensen R, Maxwell LJ, Juni P .
Consensus on the need for a hierarchical list of patient-reported pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective.
J Rheumatol 2015 Oct;42(10):1971-75. doi: 10.3899/jrheum.141384..
Keywords: Research Methodologies, Arthritis, Pain, Patient-Centered Outcomes Research
Curtis JR, Yang S, Chen L
Determining the minimally important difference in the Clinical Disease Activity Index for improvement and worsening in early rheumatoid arthritis patients.
This study determined the amount of change in the Clinical Disease Activity Index (CDAI) that represented improvement and worsening minimum clinically important differences (MCIDs). The optimal cut point for the MCID for CDAI improvement stratified for baseline disease activity was a change of 12 (high disease activity), 6 (moderate disease activity), and 1 (low disease activity). The MCID for CDAI worsening among RA patients who achieved low disease activity was 2 units.
AHRQ-funded; HS018517.
Citation: Curtis JR, Yang S, Chen L .
Determining the minimally important difference in the Clinical Disease Activity Index for improvement and worsening in early rheumatoid arthritis patients.
Arthritis Care Res 2015 Oct;67(10):1345-53. doi: 10.1002/acr.22606..
Keywords: Arthritis, Health Status
Wasserstein D, Huston LJ, Nwosu S
KOOS pain as a marker for significant knee pain two and six years after primary ACL reconstruction: a Multicenter Orthopaedic Outcomes Network (MOON) prospective longitudinal cohort study.
The researchers applied three different models of Knee injury and Osteoarthritis Outcome Score (KOOS) thresholds for significant knee pain to an anterior cruciate ligament reconstruction (ACLR) cohort to identify prevalence and risk factors. They concluded that significant knee pain is prevalent after ACLR; with those who undergo subsequent ipsilateral surgery at greatest risk.
AHRQ-funded; HS016075.
Citation: Wasserstein D, Huston LJ, Nwosu S .
KOOS pain as a marker for significant knee pain two and six years after primary ACL reconstruction: a Multicenter Orthopaedic Outcomes Network (MOON) prospective longitudinal cohort study.
Osteoarthritis Cartilage 2015 Oct;23(10):1674-84. doi: 10.1016/j.joca.2015.05.025..
Keywords: Arthritis, Surgery, Pain, Chronic Conditions, Outcomes
Busse JW, Bartlett SJ, Dougados M
Optimal strategies for reporting pain in clinical trials and systematic reviews: recommendations from an OMERACT 12 Workshop.
A group of international experts convened to address issues regarding the need to develop hierarchical lists of outcome measurement instruments for a particular outcome for metaanalyses. After discussions, most participants agreed that there is a need to develop a methodology for generation of hierarchical lists of outcome measurement instruments to guide metaanalyses.
AHRQ-funded; HS021110.
Citation: Busse JW, Bartlett SJ, Dougados M .
Optimal strategies for reporting pain in clinical trials and systematic reviews: recommendations from an OMERACT 12 Workshop.
J Rheumatol 2015 Oct;42(10):1962-70. doi: 10.3899/jrheum.141440..
Keywords: Patient-Centered Outcomes Research, Arthritis, Research Methodologies, Pain
Maradit kremers H, Larson DR, Crowson CS
AHRQ Author: Washington RE, Steiner CA
Prevalence of total hip and knee replacement in the United States.
The study’s objective was to estimate the prevalence of total hip and total knee replacement in the United States. It found that the 2010 prevalence of total hip and total knee replacement in the total U.S. population was 0.83 percent and 1.52 percent, respectively. Prevalence was higher among women than among men and increased with age.
AHRQ-authored
Citation: Maradit kremers H, Larson DR, Crowson CS .
Prevalence of total hip and knee replacement in the United States.
J Bone Joint Surg Am 2015 Sep 2;97(17):1386-97. doi: 10.2106/jbjs.n.01141..
Keywords: Healthcare Cost and Utilization Project (HCUP), Arthritis, Surgery
Bannuru RR, McAlindon TE, Sullivan MC
Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials.
The researchers evaluated the effects of alternative placebo types on pain outcomes in knee osteoarthritis. Their review concluded that all placebos are not equal, and some can trigger clinically relevant responses. Differential placebo effects can substantially alter estimates of the relative efficacies of active treatments.
AHRQ-funded; HS021396.
Citation: Bannuru RR, McAlindon TE, Sullivan MC .
Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials.
Ann Intern Med 2015 Sep 1;163(5):365-72. doi: 10.7326/m15-0623..
Keywords: Comparative Effectiveness, Arthritis, Medication, Pain, Outcomes
Bannuru RR, McAlindon TE, Sullivan MC
Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials.
The researchers evaluated the effects of alternative placebo types on pain outcomes in knee osteoarthritis. Their review concluded that all placebos are not equal, and some can trigger clinically relevant responses. Differential placebo effects can substantially alter estimates of the relative efficacies of active treatments.
AHRQ-funded; HS021396.
Citation: Bannuru RR, McAlindon TE, Sullivan MC .
Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials.
Ann Intern Med 2015 Sep 1;163(5):365-72. doi: 10.7326/m15-0623..
Keywords: Comparative Effectiveness, Arthritis, Medication, Pain, Outcomes
Bartels CM, Wong JC, Johnson SL
Rheumatoid arthritis and the prevalence of diabetic retinopathy.
The objective of this study was to examine RA as a risk factor for diabetic retinopathy compared with other vascular risk factors. It found that compared with patients without RA, the adjusted model demonstrated that patients with diabetes and RA were 28 percent less likely to have diabetic retinopathy.
AHRQ-funded; HS018368.
Citation: Bartels CM, Wong JC, Johnson SL .
Rheumatoid arthritis and the prevalence of diabetic retinopathy.
Rheumatology 2015 Aug;54(8):1415-9. doi: 10.1093/rheumatology/kev012..
Keywords: Arthritis, Risk, Eye Disease and Health, Diabetes
Singh JA, Cameron C, Noorbaloochi S
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
The researchers sought to determine whether biological drugs are associated with an increased risk of serious infection compared with traditional disease-modifying antirheumatic drugs (DMARDs). They found that standard-dose and high-dose biological drugs, with or without traditional DMARDs, are associated with an increase in serious infections in rheumatoid arthritis compared with traditional DMARDs, although low-dose biological drugs are not.
AHRQ-funded; HS021110.
Citation: Singh JA, Cameron C, Noorbaloochi S .
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
Lancet 2015 Jul 18;386(9990):258-65. doi: 10.1016/s0140-6736(14)61704-9.
.
.
Keywords: Comparative Effectiveness, Medication, Arthritis, Patient-Centered Outcomes Research
Ranganath VK, Motamedi K, Haavardsholm EA
Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy.
This study evaluated the effect of sustained American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean remission on residual joint inflammation assessed by magnetic resonance imaging (MRI) and to secondarily
evaluate other clinical definitions of remission, within an early seropositive rheumatoid arthritis (RA) cohort. It found that total MRI inflammatory scores (tenosynovitis, synovitis, osteitis) were lower among patients in clinical remission. Lower MRI scores were correlated with longer duration of Clinical Disease Activity Index (CDAI) remission.
evaluate other clinical definitions of remission, within an early seropositive rheumatoid arthritis (RA) cohort. It found that total MRI inflammatory scores (tenosynovitis, synovitis, osteitis) were lower among patients in clinical remission. Lower MRI scores were correlated with longer duration of Clinical Disease Activity Index (CDAI) remission.
AHRQ-funded; HS018517.
Citation: Ranganath VK, Motamedi K, Haavardsholm EA .
Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy.
Arthritis Care Res 2015 Jul;67(7):929-39. doi: 10.1002/acr.22541..
Keywords: Arthritis, Imaging, Comparative Effectiveness
LoVerde ZJ, Mandl LA, Johnson BK
Rheumatoid arthritis does not increase risk of short-term adverse events after total knee arthroplasty: a retrospective case-control study.
More adverse events (AE) are reported after total knee arthroplasty (TKA) for patients with rheumatoid arthritis (RA) than for patients with osteoarthritis (OA). This study evaluates 6-month postoperative AE in a high-volume center in a contemporary RA cohort. It found that in a high-volume center, with high RA-specific experience, RA does not increase postoperative AE.
AHRQ-funded; HS016075.
Citation: LoVerde ZJ, Mandl LA, Johnson BK .
Rheumatoid arthritis does not increase risk of short-term adverse events after total knee arthroplasty: a retrospective case-control study.
J Rheumatol 2015 Jul;42(7):1123-30. doi: 10.3899/jrheum.141251..
Keywords: Adverse Events, Arthritis, Surgery, Comparative Effectiveness, Patient-Centered Outcomes Research
Kim SC, Glynn RJ, Giovannucci E
Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study.
This study assessed the risk of high-grade cervical dysplasia, a surrogate endpoint for cervical cancer and cervical cancer, in women with systemic inflammatory diseases (SID), including IBD, psoriasis, rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE), compared with the risk in women without SID. It found that the risk of high-grade cervical dysplasia and cervical cancer was 1.5 times higher in women with RA and SLE than in those without SID.
AHRQ-funded; HS018533.
Citation: Kim SC, Glynn RJ, Giovannucci E .
Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study.
Ann Rheum Dis 2015 Jul;74(7):1360-7. doi: 10.1136/annrheumdis-2013-204993..
Keywords: Arthritis, Risk, Women, Cancer: Cervical Cancer, Cancer
Yazdany J, Dudley RA, Chen R
Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
The aim of this study was to conduct the first systematic, national investigation of how Part D plans cover biologic disease-modifying anti-rheumatic drugs (DMARDs) and to determine patients’ financial burden under current cost-sharing structures. It found that all Medicare Part D drug plans cover at least 1 biologic DMARD, access is highly controlled through prior authorization requirements, and beneficiaries face significant cost sharing.
AHRQ-funded; HS017723; HS016772.
Citation: Yazdany J, Dudley RA, Chen R .
Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Arthritis Rheumatol 2015 Jun;67(6):1474-80. doi: 10.1002/art.39079..
Keywords: Medicare, Medication, Healthcare Costs, Arthritis
Kavanaugh A, Lee SJ, Curtis JR
Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
There is increasing interest in discontinuing biological therapies for patients with rheumatoid arthritis achieving good clinical responses, provided patients maintain clinical benefit. Using data from the Corrona registry, the investigators found that discontinuation of a first course of tumour necrosis factor inhibitor may be associated with persistent clinical benefit. Half of the registry patients included in the study maintained response through 20 months.
AHRQ-funded; HS018517.
Citation: Kavanaugh A, Lee SJ, Curtis JR .
Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
Ann Rheum Dis 2015 Jun;74(6):1150-5. doi: 10.1136/annrheumdis-2014-206435.
.
.
Keywords: Medication, Patient-Centered Outcomes Research, Registries, Arthritis
Solomon DH, Reed GW, Kremer JM
Disease activity in rheumatoid arthritis and the risk of cardiovascular events.
The researchers studied whether time-averaged disease activity in rheumatoid arthritis (RA) correlates with cardiovascular (CV) events. They found that reduced time-averaged disease activity in RA is associated with fewer CV events.
AHRQ-funded; HS018517.
Citation: Solomon DH, Reed GW, Kremer JM .
Disease activity in rheumatoid arthritis and the risk of cardiovascular events.
Arthritis Rheumatol 2015 Jun;67(6):1449-55. doi: 10.1002/art.39098.
.
.
Keywords: Cardiovascular Conditions, Heart Disease and Health, Arthritis, Risk, Stroke
Yun H, Xie F, Delzell E
Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
The researchers compare the subsequent risk of hospitalized infections associated with specific biologic agents among RA patients previously hospitalized for infection while receiving anti-tumor necrosis factor (anti-TNF) therapy. They found that among rheumatoid arthritis patients who experienced a hospitalized infection while on anti-TNF therapy, abatacept and etanercept were associated with the lowest risk of a subsequent infection compared to other biologic therapies.
AHRQ-funded; HS021694; HS023009; HS018517.
Citation: Yun H, Xie F, Delzell E .
Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
Ann Rheum Dis 2015 Jun;74(6):1065-71. doi: 10.1136/annrheumdis-2013-204011..
Keywords: Arthritis, Healthcare-Associated Infections (HAIs), Healthcare-Associated Infections (HAIs), Patient-Centered Outcomes Research, Patient Safety
Curtis JR, Xie F, Yun H
Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
The researchers evaluated rates of hospitalized infection among patients treated with biologic agents for RA who subsequently initiated denosumab in order to assess whether rates of infection were increased with concurrent biologic agent use for RA. They found that the rate of hospitalized infection among RA patients receiving denosumab concurrently with biologic agents for RA was not increased compared to those receiving zoledronate.
AHRQ-funded; HS018517
Citation: Curtis JR, Xie F, Yun H .
Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
Arthritis Rheumatol. 2015 Jun;67(6):1456-64. doi: 10.1002/art.39075..
Keywords: Arthritis, Healthcare-Associated Infections (HAIs), Risk, Patient Safety, Comparative Effectiveness
Burton MJ, Curtis JR, Yang S
Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study.
The researchers evaluated the safety of current treatment regimens for patients with rheumatoid arthritis (RA) and HBV in a large US cohort. They found a low rate of hepatotoxicity among a large cohort of US veterans with RA and HBV infection who were prescribed conventional RA therapies. Also, there were comparable rates of hepatotoxicity between biologic and nonbiologic disease-modifying anti-rheumatic drugs.
AHRQ-funded; HS023710.
Citation: Burton MJ, Curtis JR, Yang S .
Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study.
Arthritis Res Ther 2015 May 22;17:136. doi: 10.1186/s13075-015-0628-z..
Keywords: Arthritis, Patient Safety, Medication, Hepatitis, Adverse Drug Events (ADE)
Petrov ME, Goodin BR, Cruz-Almeida Y
Disrupted sleep is associated with altered pain processing by sex and ethnicity in knee osteoarthritis.
This study examines the association between sleep disruption with increased pain sensitivity and enhanced pain facilitation in addition to reduced pain inhibition in persons with chronic pain such as knee OA. It found that disrupted sleep was associated with altered pain processing by sex and ethnicity/race.
AHRQ-funded; HS013852.
Citation: Petrov ME, Goodin BR, Cruz-Almeida Y .
Disrupted sleep is associated with altered pain processing by sex and ethnicity in knee osteoarthritis.
J Pain 2015 May;16(5):478-90. doi: 10.1016/j.jpain.2015.02.004..
Keywords: Pain, Sleep Problems, Arthritis, Racial and Ethnic Minorities, Sex Factors
Zhang J, Xie F, Delzell E
Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
The purpose of this study was to examine whether concomitant methotrexate (MTX) use is associated with better biologic persistence and whether self-administered anti–tumor necrosis factor (anti-TNF) therapies are used at reduced doses in real world clinical care settings, not just clinical trials. It found that use of concomitant MTX is associated with greater persistence to biologic therapy.
AHRQ-funded; HS018517.
Citation: Zhang J, Xie F, Delzell E .
Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
Arthritis Care Res 2015 May;67(5):624-32. doi: 10.1002/acr.22510..
Keywords: Arthritis, Comparative Effectiveness, Patient-Centered Outcomes Research, Treatments
Singh JA, Inacio MC, Namba RS
Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study.
This study examined whether an underlying diagnosis of rheumatoid arthritis (RA) or osteoarthritis (OA) impacts the 90-day readmission rates after total hip arthroplasty (THA) or total knee arthroplasty (TKA). The 90-day post arthroplasty readmission risk after THA or TKA is higher in patients with rheumatoid arthritis (RA) compared to osteoarthritis.
AHRQ-funded; HS021110.
Citation: Singh JA, Inacio MC, Namba RS .
Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study.
Arthritis Care Res 2015 May;67(5):718-24. doi: 10.1002/acr.22497..
Keywords: Arthritis, Hospital Readmissions, Arthritis, Surgery
Yun H, Xie F, Delzell E
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.
This study evaluated whether the risks of herpes zoster (HZ) differed by biologic agents with different mechanisms of action (MOAs) in older rheumatoid arthritis (RA) patients. Using Medicare data from 2006–2011, the researchers found that among RA patients, the rate and adjusted hazard ratios of HZ were similar among biologic agents, including those with non–tumor necrosis factor mechanisms of action.
AHRQ-funded; HS021694; HS018517.
Citation: Yun H, Xie F, Delzell E .
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.
Arthritis Care Res 2015 May;67(5):731-6. doi: 10.1002/acr.22470..
Keywords: Arthritis, Risk, Patient Safety, Patient-Centered Outcomes Research
Newman ED, Lerch V, Billet J
Improving the quality of care of patients with rheumatic disease using patient-centric electronic redesign software.
To improve the quality of care for patients with rheumatic disease, the researchers developed electronic data capture, aggregation, display, and documentation software. They found that their software was adopted for use by 86% of patients and rheumatologists. They concluded that the software was well-adopted by patients and providers. Post-implementation, significant improvements in quality of care, efficiency of care, and productivity were demonstrated.
AHRQ-funded; 290200600019I.
Citation: Newman ED, Lerch V, Billet J .
Improving the quality of care of patients with rheumatic disease using patient-centric electronic redesign software.
Arthritis Care Res 2015 Apr;67(4):546-53. doi: 10.1002/acr.22479..
Keywords: Health Information Technology (HIT), Quality of Care, Arthritis, Patient-Centered Outcomes Research